Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer

T. C. Merigan, J. G. Gallagher, Richard B Pollard, A. M. Arvin

Research output: Contribution to journalArticle

24 Scopus citations


Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.

Original languageEnglish (US)
Pages (from-to)193-195
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Issue number1
StatePublished - 1981
Externally publishedYes


ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this